ADMA Biologics (ADMA) Stock Overview
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ADMA Community Fair Values
Create NarrativeSee what 73 others think this stock is worth. Follow their fair value or set your own to get alerts.
ADMA Biologics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.37 |
| 52 Week High | US$25.67 |
| 52 Week Low | US$13.50 |
| Beta | 0.46 |
| 1 Month Change | 4.84% |
| 3 Month Change | -18.93% |
| 1 Year Change | -19.57% |
| 3 Year Change | 507.51% |
| 5 Year Change | 749.17% |
| Change since IPO | 80.19% |
Recent News & Updates
Recent updates
ADMA Biologics: Strong Product Mix, Growing Margins And Compelling Upside
Sep 03ADMA Biologics: Premium Valuation Justified By Strong Fundamentals And Future Potential
Mar 21Revenues Not Telling The Story For ADMA Biologics, Inc. (NASDAQ:ADMA)
Feb 26
ADMA Biologics: Recent Pullback Is A Perfect Opportunity To Add
Feb 06Does ADMA Biologics (NASDAQ:ADMA) Have A Healthy Balance Sheet?
Dec 31ADMA Biologics: Capitalizing On A $20 Billion IG Market With ASCENIV
Dec 02Subdued Growth No Barrier To ADMA Biologics, Inc. (NASDAQ:ADMA) With Shares Advancing 36%
Nov 26Valuation analysis
11-NOV-2024Actual company guidance: 2024: 415 MUSD revenue (S24) and net income 120 MUSD (E24), 2025: 465 MUSD (S25), 165 MUSD net income (E25)Market cap of 5.35 BUSD (P) at 22.62/share: P/S24 = 12.9,ADMA Biologics, Inc.'s (NASDAQ:ADMA) 27% Price Boost Is Out Of Tune With Revenues
Oct 09ADMA Biologics: Riding High On ASCENIV's Success
Oct 02ADMA Biologics, Inc.'s (NASDAQ:ADMA) Intrinsic Value Is Potentially 57% Above Its Share Price
Sep 06
ASCENIV Drives Revenue Surge, Shaping A Bright Future For The Biotech Leader
ADMA Biologics showcases rapid revenue growth and operational efficiency, with ASCENIV's success significantly impacting future growth.ADMA Biologics' (NASDAQ:ADMA) Strong Earnings Are Of Good Quality
Aug 16ADMA Biologics: A Compelling GARP Stock For Biotech Investors
Jul 27ADMA Biologics, Inc. (NASDAQ:ADMA) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Jul 24Is ADMA Biologics (NASDAQ:ADMA) Using Too Much Debt?
Jul 17Is ADMA Biologics, Inc. (NASDAQ:ADMA) Trading At A 43% Discount?
May 30ADMA Biologics, Inc. Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next
May 13Giving ADMA Biologics A Well-Deserved 'Booyah'
May 12ADMA Biologics, Inc.'s (NASDAQ:ADMA) Prospects Need A Boost To Lift Shares
May 08Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?
Apr 04Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)
Apr 03ADMA Biologics: On A Roll Entering 2024
Jan 19Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?
Jan 09ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Jan 09We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Oct 25We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Jun 10The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet
May 12ADMA Biologics: Strong Growth Is Clearing The Path To Profitability
Aug 21ADMA Biologics GAAP EPS of -$0.07, revenue of $33.9M
Aug 10Shareholder Returns
| ADMA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.5% | 0.8% | -0.9% |
| 1Y | -19.6% | 2.6% | 20.1% |
Return vs Industry: ADMA underperformed the US Biotechs industry which returned 2.6% over the past year.
Return vs Market: ADMA underperformed the US Market which returned 20.1% over the past year.
Price Volatility
| ADMA volatility | |
|---|---|
| ADMA Average Weekly Movement | 5.8% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ADMA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ADMA's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 685 | Adam Grossman | www.admabiologics.com |
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities.
ADMA Biologics, Inc. Fundamentals Summary
| ADMA fundamental statistics | |
|---|---|
| Market cap | US$3.69b |
| Earnings (TTM) | US$208.93m |
| Revenue (TTM) | US$474.17m |
Is ADMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ADMA income statement (TTM) | |
|---|---|
| Revenue | US$474.17m |
| Cost of Revenue | US$222.86m |
| Gross Profit | US$251.32m |
| Other Expenses | US$42.39m |
| Earnings | US$208.93m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 05, 2025
| Earnings per share (EPS) | 0.88 |
| Gross Margin | 53.00% |
| Net Profit Margin | 44.06% |
| Debt/Equity Ratio | 18.4% |
How did ADMA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/03 06:47 |
| End of Day Share Price | 2025/11/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ADMA Biologics, Inc. is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kristen Kluska | Cantor Fitzgerald & Co. |
| Prem Chulaki | Crisp Idea |
| Sheshadri N. | Crisp Idea |